Show simple item record

dc.contributor.authorSTORDAL, BRITTA KRISTINA
dc.date.accessioned2012-06-15T09:30:41Z
dc.date.available2012-06-15T09:30:41Z
dc.date.issued2007
dc.date.submitted2007en
dc.identifier.citationStordal, B., Pavlakis, N. and Davey, R., Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review., Cancer Treatment Reviews, 33, 4, 2007, 347 - 357en
dc.identifier.otherY
dc.identifier.urihttp://hdl.handle.net/2262/63716
dc.descriptionPUBLISHEDen
dc.description.abstractOxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ?cisplatinresistant? cancer. We identified 25 pre-clinical cell models of platinum resistance and 24 clinical trials reporting oxaliplatin based salvage therapy for cisplatin-resistant cancer. The pre-clinical data suggests that there is cross-resistance between cisplatin and oxaliplatin in low-level resistance models. In models with high level resistance (>10 fold) there is less cross resistance between cisplatin and oxaliplatin, which may be a reason why oxaliplatin is thought to be active in cisplatin-resistant cancer. In clinical trials where oxaliplatin has been used as part of salvage therapy for patients who have failed cisplatin or carboplatin combination chemotherapy, there was a much lower response rate in patients with platinum-refractory or resistant cancers compared to platinum-sensitive cancers. This suggests that there may be cross-resistance between cisplatin and oxaliplatin in the clinic. Oxaliplatin as a single agent had a poor response rate in cisplatin refractory and resistant cancer. Oxaliplatin performed better in combination with other agents for the treatment of platinum resistant/refractory cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer.en
dc.format.extent347en
dc.format.extent357en
dc.language.isoenen
dc.publisherWB Saundersen
dc.relation.ispartofseriesCancer Treatment Reviews;33, 4
dc.rightsYen
dc.subjectCisplatinen
dc.subjectOxaliplatinen
dc.titleOxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review.en
dc.title.alternativeOxaliplatin in Cisplatin-Resistant Canceren
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/stordalb
dc.identifier.rssinternalid79795


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record